NEW YORK, April 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Allergan Inc. (NYSE: AGN), Boston Scientific Corporation (NYSE: BSX), Covidien Plc (NYSE: COV) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1089-100free.
Teva Pharmaceutical Industries Ltd. Analyst Notes
On April 8, 2014, Teva Pharmaceutical Industries Ltd. (Teva) announced that its generic equivalent to Lovaza (Omega-3-Acid Ethyl Esters Capsules, USP) has been approved by the Food and Drug Administration (FDA) in the U.S. Teva, the only company so far to receive a FDA approval for generic Lovaza, plans to start the shipping of the drug immediately. Lovaza Capsules, marketed by GlaxoSmithKline, had annual sales of approximately $1.1 billion in the U.S., according to IMS data as of December 2013. The development, however, failed to lift the stock which ended lower for the third consecutive day on the announcement. Teva's stock came under pressure as the Company battles to delay the possible market entry of generic versions of its top-selling multiple-sclerosis drug Copaxone, which accounts for more than half of the Company's profits. The full analyst notes on Teva are available to download free of charge at:
Allergan Inc. Analyst Notes
On April 4, 2014, Allergan Inc. (Allergan) announced that the Company plans to hold its Q1 2014 earnings conference call on May 7, 2014, at 8:00 a.m. PT. The Company informed that David Pyott, the Chairman of the Board and CEO, and Jeff Edwards, Executive Vice President, Finance and Business Development, CFO will discuss the Company's performance during the call. According to Zacks Investment Research data, the consensus EPS forecast for Q1 2014 is $1.12, which is the upper end of the guidance range provided by Allergan. In its Q1 2014 outlook released earlier, the Company expected non-GAAP diluted EPS in the range of $1.09 and $1.12, with net sales to vary between $1.5 billion and $1.6 billion. The full analyst notes on Allergan are available to download free of charge at:
Boston Scientific Corporation Analyst Notes
On April 7, 2014, Boston Scientific Corporation (Boston Scientific) announced that its Expect[TM] Slimline (SL) Needle has received clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe. According to the Company, the product's design incorporates extensive feedback from the customers and is used to collect tissue samples to diagnose and stage malignancies in organs adjacent to the gastrointestinal tract. Expect Slimline Needle, now available globally, is on contract with four leading group purchasing organizations. David Pierce, President, Endoscopy, Boston Scientific, said, "As the leader in GI endoscopic devices, we have made it a priority to broaden our product portfolio continually to provide physicians with a variety of device solutions to meet their needs. Bringing the Expect Slimline Needle to market in a very short period of time truly underscores our commitment to listening to customers." The full analyst notes on Boston Scientific are available to download free of charge at:
Covidien Plc Analyst Notes
On April 9, 2014, Covidien Plc's (Covidien) stock moved up 2.29% to end the day at $71.80. The rise in Covidien's stock was in line with the broader market indexes that moved up after International Monetary Fund (IMF) reiterated its 2014 growth forecast for the U.S. at 2.8%, which is the highest among advanced economies. U.S. markets also rallied as Federal Reserve's latest meeting minutes eased concerns over timing of future interest-rate increases, and as Q1 2014 earnings season kicked-off on a strong note. Covidien's stock opened the session at $70.56 and fluctuated between $70.05 and $71.81. Over the past three months, the stock has gained 3.06%, outperforming the S&P 500 index that gained 1.62% over the same period. The full analyst notes on Covidien are available to download free of charge at:
Thermo Fisher Scientific Inc. Analyst Notes
On April 8, 2014, Thermo Fisher Scientific Inc. (Thermo Fisher) announced that the Company plans to release its Q1 2014 results on April 23, 2014, before the opening of the market, followed by a conference call at 8:30 a.m. EDT to discuss the performance. According to Zacks Investment Research data, the consensus EPS forecast for Q1 2014 is $1.41. The full analyst notes on Thermo Fisher are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. This release was produced by first_testproducer last_testproducer, a CFA charter-holder and reviewed by Ananya Ghosh, a CFA charter-holder. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Please visit http://www.analystsreview.com/disclaimer for our full legal disclaimer. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review